IRAK1 Antibody

Basic Research Questions

• What is IRAK1 and why is it important in immunological research?

  IRAK1 (Interleukin-1 receptor-associated kinase 1) is a critical serine/threonine protein kinase that plays a fundamental role in innate immune response signaling. It functions downstream of Toll-like receptors (TLRs) and the interleukin-1 receptor (IL-1R). Upon receptor activation, IRAK1 is recruited by MyD88 to the receptor-signaling complex, where it undergoes phosphorylation by IRAK4, followed by autophosphorylation and kinase activation .

  The significance of IRAK1 lies in its central position within multiple inflammatory signaling cascades. It forms a cytosolic complex with TRAF6 after activation, ultimately leading to NF-κB pathway activation and expression of pro-inflammatory cytokines. This process is vital for the body's defense against pathogens and regulation of immune responses .

• Which applications are most suitable for IRAK1 antibodies?

  IRAK1 antibodies can be employed in numerous research applications:

  Application	Typical Dilutions	Notes
  Western Blot (WB)	1:500-1:3000	Most commonly validated application
  Immunoprecipitation (IP)	0.5-4.0 μg per 1-3 mg lysate	Effective for protein interaction studies
  Immunohistochemistry (IHC)	1:300-1:1200	Validated in multiple tissue types
  Immunofluorescence (IF/ICC)	1:200-1:800	Good for subcellular localization studies
  Flow Cytometry (Intracellular)	0.40 μg per 10^6 cells	Requires cell permeabilization
  ELISA	Application-dependent	Used for quantitative detection

  When selecting an application, consider that IRAK1 forms complexes with other proteins after activation, which may affect epitope accessibility in certain techniques .

• How can I distinguish between different phosphorylation states of IRAK1?

  IRAK1 undergoes extensive phosphorylation during activation, resulting in multiple phosphorylated species with different molecular weights (typically observed between 68-105 kDa) . To distinguish between phosphorylation states:

  • Use phospho-specific antibodies targeting key phosphorylation sites (such as those detecting IRAK4-mediated phosphorylation)

  • Employ lambda phosphatase (λPPase) treatment as a control to collapse the higher molecular weight bands to confirm phosphorylation states

  • Analyze samples with and without stimulation (e.g., IL-1β) to observe the transition from unmodified to modified forms

  • Use SDS-PAGE with lower percentage gels (6-8%) to better resolve the different phosphorylated species

  For comprehensive analysis, researchers should combine these approaches with proteomic methods such as mass spectrometry to identify specific phosphorylation sites .

• What positive controls should I use when validating IRAK1 antibodies?

  When validating IRAK1 antibodies, the following positive controls are recommended:

  Cell Lines	Tissue Types	Special Conditions
  HeLa	Human lung cancer tissue	IL-1β stimulation (5-15 min) for activated forms
  HEK-293 (especially IL-1R-expressing)	Human placenta	Compare with IRAK1 KO controls
  A549	Mouse/rat ovary	Stimulation with TLR ligands (e.g., Pam3CSK4)
  MCF-7	Rat intestine	Combined with inhibitor controls
  RAW 264.7	-	-

  For the most rigorous validation, include IRAK1 knockout or knockdown samples as negative controls to confirm antibody specificity .

Intermediate Research Questions

• How can I effectively measure IRAK1 kinase activity in cell extracts?

  Measuring endogenous IRAK1 kinase activity in cell extracts requires specialized techniques beyond simple Western blotting. A recommended approach based on research methodologies:

  1. Immunoprecipitation-based kinase assay:

     • Immunoprecipitate IRAK1 from cell extracts (0.5 mg protein) using 0.5 μg of specific antibody for 1 hour at 4°C

     • Incubate with Protein G-Sepharose beads (15 μl packed volume) for an additional hour

     • Wash with high-salt buffer (containing 0.5 M NaCl) followed by kinase assay buffer

  2. Activity measurement using Pellino1 substrate:

     • Resuspend beads in kinase assay buffer with 0.5 mM [γ-32P]ATP and GST-Pellino1 (0.5 μg/reaction)

     • Include IRAK4 inhibitor (e.g., IRAK4-IN-1) to prevent interference from co-precipitated IRAK4

     • Include JNK-IN-7 (IRAK1 inhibitor) as a control to confirm specificity

     • Incubate for 30 min at 30°C with continuous agitation

  3. Analysis:

     • Subject reactions to SDS-PAGE and autoradiography to detect phosphorylated Pellino1

     • Compare samples with and without stimulation (e.g., IL-1) to observe activation kinetics

  This assay provides a reliable readout of IRAK1-specific activity in complex cell extracts .

• What are the key differences between IRAK1 and IRAK4 antibodies and their experimental applications?

  Understanding the distinctions between IRAK1 and IRAK4 antibodies is crucial for experimental design:

  Feature	IRAK1 Antibodies	IRAK4 Antibodies
  Molecular Weight Detection	68-105 kDa (varies with phosphorylation)	~55 kDa
  Activation State	Inactive in unstimulated cells, activated upon stimulation	Constitutively active in most cell types
  Co-immunoprecipitation	Pulls down IRAK4 after stimulation	Can pull down IRAK1 after stimulation
  Activity Measurement	Use Pellino1 substrate with IRAK4 inhibitor	Use Pellino1 substrate with IRAK1 inhibitor
  Response to Stimulation	Dramatic mobility shift after IL-1 stimulation	No significant increase in intrinsic activity after stimulation

  When designing experiments involving both kinases, researchers can simultaneously measure IRAK1 and IRAK4 activities in IRAK4 immunoprecipitates by including appropriate pharmacological inhibitors in the assays .

• How do post-translational modifications affect IRAK1 antibody recognition?

  IRAK1 undergoes extensive post-translational modifications (PTMs) that can significantly impact antibody recognition:

  • Phosphorylation: IL-1 stimulation induces hyperphosphorylation, creating multiple high-molecular-weight species (80-105 kDa) that may alter epitope accessibility

  • Ubiquitination: IRAK1 undergoes K63-linked polyubiquitination following activation, which can mask epitopes, particularly for antibodies targeting lysine-rich regions

  • Sumoylation: When sumoylated, IRAK1 translocates to the nucleus, potentially affecting antibody access in subcellular fractionation experiments

  To address these challenges:

  1. Use antibodies targeting different epitopes for comprehensive detection

  2. Include deubiquitylation (USP2) and dephosphorylation (λPPase) treatments to collapse modified forms for total IRAK1 detection

  3. For studies focusing on specific modifications, use modification-specific antibodies or enrichment techniques

  4. When examining nuclear functions, carefully validate antibodies for detecting sumoylated forms

  These approaches help ensure accurate detection regardless of IRAK1's modification state.

• What approaches can resolve contradictory IRAK1 antibody results?

  When facing contradictory results with IRAK1 antibodies, implement this systematic troubleshooting approach:

  1. Validate antibody specificity:

     • Test with IRAK1 knockout/knockdown samples as negative controls

     • Compare multiple antibodies targeting different epitopes

     • Use recombinant IRAK1 as a positive control

  2. Address technical variables:

     • Optimize sample preparation (lysis buffers may affect complex integrity)

     • Include phosphatase/deubiquitinase treatments to standardize modification states

     • Test different blocking agents (BSA vs. non-fat dry milk)

  3. Consider biological variables:

     • IRAK1 activation state varies significantly between stimulated/unstimulated conditions

     • Cell type-specific differences in IRAK1 expression and modification patterns

     • Timing of stimulation affects detection (peak activation at 5-15 minutes post-IL-1 stimulation)

  4. Use complementary approaches:

     • Combine immunoblotting with activity assays

     • Confirm protein interactions with reciprocal co-immunoprecipitation

     • Employ mass spectrometry for unbiased identification

  This comprehensive approach helps resolve discrepancies and ensures reliable results.

Advanced Research Questions

• How can IRAK1 antibodies be optimized for dual immunoprecipitation-activity assays?

  Developing robust dual immunoprecipitation-activity assays for IRAK1 requires careful optimization:

  1. Antibody selection and validation:

     • Choose antibodies that efficiently immunoprecipitate native IRAK1 without interfering with its kinase domain

     • Validate that the antibody can pull down ~90% of IRAK1 from cell extracts (verify by analyzing supernatants)

     • Ensure the antibody does not block substrate accessibility in kinase assays

  2. Lysis and immunoprecipitation conditions:

     • Use buffers containing 50 mM Tris-HCl (pH 7.5), 1 mM EGTA, 1 mM EDTA, 1% Triton X-100, 1 mM sodium orthovanadate, 50 mM sodium fluoride, 5 mM sodium pyrophosphate, 0.27 M sucrose, 0.1% β-mercaptoethanol, and protease inhibitors

     • Perform immunoprecipitation with 0.5 μg antibody per 0.5 mg protein for 1 hour at 4°C

     • Wash beads three times with lysis buffer containing 0.5 M NaCl followed by three washes with kinase buffer

  3. Activity assay optimization:

     • Resuspend in kinase buffer (50 mM Tris-HCl pH 7.5, 0.1 mM EGTA, 2 mM DTT, 10 mM magnesium acetate)

     • Add GST-Pellino1 (0.5 μg/reaction) and 0.5 mM ATP (labeled if quantification is needed)

     • Include specific inhibitors to distinguish IRAK1 activity (JNK-IN-7) from co-precipitated kinases (IRAK4-IN-1)

     • Incubate for 30 min at 30°C with continuous agitation

  4. Controls and validation:

     • Include unstimulated vs. stimulated (IL-1β or TLR ligands) samples

     • Perform parallel assays with non-specific antibodies to control for background

     • Use IRAK1-deficient cells as negative controls

  This approach enables reliable measurement of IRAK1 activity directly from immunoprecipitates while maintaining specificity.

• What strategies can distinguish between IRAK1's scaffold and kinase functions in experimental systems?

  IRAK1 possesses both kinase activity and scaffold functions, which can be challenging to distinguish experimentally. The following strategies can help separate these functions:

  1. Pharmacological approach:

     • Use specific IRAK1 kinase inhibitors (e.g., JNK-IN-7) that block catalytic activity without disrupting protein-protein interactions

     • Compare effects with structurally related control compounds that don't inhibit IRAK1 (e.g., JNK-IN-8)

     • Monitor downstream signaling events dependent on kinase activity (e.g., Pellino1 phosphorylation) vs. scaffold-dependent events (e.g., TRAF6 recruitment)

  2. Genetic approach:

     • Express kinase-dead IRAK1 mutants that maintain structural integrity but lack catalytic activity

     • Use domain-specific deletion mutants that selectively disrupt binding to specific partners

     • Complement IRAK1-deficient cells with these constructs to identify which functions are rescued

  3. Temporal dissection:

     • Exploit the observation that IRAK1's scaffold function occurs immediately upon recruitment to receptor complexes, while kinase activity peaks later (5-15 minutes post-stimulation)

     • Perform time-course experiments with inhibitor addition at different points

  4. Biochemical separation:

     • Use size-exclusion chromatography to separate monomeric IRAK1 (primarily kinase function) from complex-associated IRAK1 (scaffold function)

     • Analyze the complexes by mass spectrometry to identify associated proteins

  These approaches provide complementary information about the distinct roles of IRAK1 in signaling pathways.

• How can IRAK1 antibodies be used effectively in cancer research applications?

  IRAK1 is increasingly recognized as a potential therapeutic target in various cancers. Here's how to effectively use IRAK1 antibodies in cancer research:

  1. Expression analysis in clinical samples:

     • Use IHC with validated IRAK1 antibodies on tissue microarrays to correlate expression with patient outcomes

     • Optimize antigen retrieval (TE buffer pH 9.0 or citrate buffer pH 6.0) for consistent results

     • Develop scoring systems based on intensity and proportion of positive cells

     • Compare with normal tissues to establish cancer-specific expression patterns

  2. Functional studies in cancer models:

     • Use Western blotting to assess IRAK1 activation state in response to treatments

     • Combine with phospho-specific antibodies to monitor activation of downstream pathways (NF-κB, MAPK)

     • Perform immunoprecipitation to identify cancer-specific interaction partners

     • Use flow cytometry for single-cell analysis of IRAK1 expression in heterogeneous tumors

  3. IRAK1-targeted therapeutic evaluation:

     • Monitor IRAK1 expression/activation before and after treatment with inhibitors like pacritinib

     • Assess effects on PD-L1 expression in combination with IRAK1 inhibition (flow cytometry approach)

     • Perform IHC on xenograft tumors to correlate IRAK1 inhibition with growth suppression

  4. Immune contexture analysis:

     • Combine IRAK1 staining with immune cell markers to assess correlation with tumor-infiltrating immune cells

     • Analyze relationship between IRAK1 expression and immune subtypes (inflammatory, wound healing, etc.)

     • Use multiplexed IF to study IRAK1 in both tumor and immune cells within the microenvironment

  Cancer-related research applications benefit from examining IRAK1 in both tumor cells and the surrounding immune microenvironment.

• What are the technical considerations for measuring IRAK1 in primary human samples?

  Working with primary human samples presents unique challenges for IRAK1 analysis:

  1. Sample collection and processing:

     • Process samples immediately to preserve phosphorylation states and protein complexes

     • Use protease, phosphatase, and deubiquitinase inhibitors in lysis buffers

     • For blood-derived cells, avoid prolonged ex vivo handling that may activate TLR signaling

     • Consider flash-freezing tissue samples before lysis if immediate processing isn't possible

  2. Cell-type specific considerations:

     • For primary macrophages, use gentle cell dissociation methods to maintain receptor integrity

     • In THP1 monocytes and primary macrophages, IRAK1 responses to TLR stimulation may differ from cell lines

     • IRAK1 expression levels vary significantly between immune and non-immune cells

  3. Stimulation protocols:

     • For consistent activation, use standardized concentrations of stimuli (e.g., IL-1β, Pam3CSK4)

     • Include time-course experiments to capture both early (5-15 min) and late (30-60 min) activation events

     • Control for donor variability by including technical replicates

  4. Analysis approach:

     • For limited samples, consider sequential immunoprecipitation to maximize data output

     • With surgical specimens, use laser capture microdissection to isolate specific regions before analysis

     • Combine with single-cell approaches for heterogeneous samples

  5. Controls and normalization:

     • Include stimulated cell lines as technical controls across experiments

     • For patient samples, normalize to appropriate housekeeping proteins (GAPDH)

     • Consider paired normal/tumor tissue when available

  These considerations help ensure reliable IRAK1 analysis in valuable and often limited primary human samples.

• How can multiplexed approaches be used to study IRAK1 interaction networks?

  Investigating IRAK1's complex interaction networks benefits from multiplexed experimental approaches:

  1. Co-immunoprecipitation coupled with mass spectrometry:

     • Perform IRAK1 immunoprecipitation from cells in different activation states

     • Analyze by liquid chromatography-tandem mass spectrometry (LC-MS/MS)

     • Compare interactomes between resting and activated states to identify dynamic interactions

     • Validate key interactions with reciprocal co-IP and Western blotting

  2. Proximity labeling techniques:

     • Generate IRAK1 fusion proteins with BioID or APEX2 proximity labeling enzymes

     • Express in relevant cell types and perform stimulation experiments

     • Purify biotinylated proteins and identify by mass spectrometry

     • This approach captures transient or weak interactions missed by co-IP

  3. Multiplexed immunofluorescence imaging:

     • Use different fluorophore-conjugated antibodies against IRAK1 and interaction partners

     • Perform confocal microscopy to assess co-localization

     • Apply for tissue sections to visualize interactions in physiological contexts

     • Validated in subcellular co-localization studies of IRAK1 with VASP

  4. Protein complementation assays:

     • Fuse split reporter fragments (split GFP, luciferase) to IRAK1 and potential partners

     • Measure reconstituted activity when proteins interact

     • Apply in live cells to monitor dynamic interactions during signaling

     • Use with inhibitors to distinguish modification-dependent interactions

  5. Multiplexed ELISA/Luminex approaches:

     • Develop bead-based assays for simultaneous detection of IRAK1 complexes

     • Measure multiple interaction partners from limited samples

     • Quantify changes in complex formation following stimulation or inhibition

  These multiplexed approaches provide comprehensive views of IRAK1's dynamic interaction network during signaling events.

• What are the best approaches for studying IRAK1's role in immunotherapy response prediction?

  Recent evidence suggests IRAK1 expression may predict immunotherapy responses. Here are optimal approaches to study this relationship:

  1. Patient sample analysis:

     • Perform IHC for IRAK1 on pre-treatment biopsies from immunotherapy patients

     • Develop standardized scoring systems (high vs. low expression)

     • Correlate with objective response rates and progression-free survival

     • Include PD-L1 co-staining to assess relationship with this established biomarker

  2. Functional experiments in cancer models:

     • Test combination of IRAK1 inhibitors (e.g., pacritinib) with immune checkpoint blockade

     • Monitor changes in PD-L1 expression by flow cytometry after IRAK1 inhibition

     • Standardize treatment protocols (0.5-1 μM pacritinib for 48h) to assess PD-L1 upregulation

     • Assess effects on tumor-infiltrating immune cells in mouse models

  3. Immune cell profiling:

     • Analyze correlation between IRAK1 expression and immune cell populations (CD8+ T cells, M1/M2 macrophages)

     • Use CIBERSORT or TIMER algorithms for computational deconvolution of bulk tumor data

     • Classify samples into immune subtypes (C1-C6) to correlate with IRAK1 expression

     • Perform multiplexed immunofluorescence on tissue sections

  4. Clinical data analysis:

     • Stratify patient cohorts by IRAK1 expression levels (high vs. low)

     • Compare objective response rates to anti-PD-L1 therapy between groups

     • In the IMvigor210 cohort, patients with low IRAK1 had better outcomes (27% vs. 18% response rate, p=0.041)

     • Develop predictive models incorporating IRAK1 with other biomarkers

  These approaches can help establish IRAK1 as a predictive biomarker for immunotherapy response and guide combination treatment strategies.

• How can researchers distinguish between different IRAK family members in experimental systems?

  The IRAK family consists of four members (IRAK1, IRAK2, IRAK3/M, and IRAK4) with structural similarities that can complicate specific detection. Here are strategies to ensure specificity:

  1. Antibody selection and validation:

     • Choose antibodies raised against divergent regions between IRAK family members

     • Validate specificity by testing against recombinant IRAK proteins (IRAK1, IRAK2, IRAK4)

     • Confirm with knockout or knockdown controls for each family member

     • Western blot analysis should show distinct molecular weights (IRAK1: 68-80 kDa, IRAK4: ~55 kDa)

  2. Activity-based discrimination:

     • IRAK1 and IRAK4 both phosphorylate Pellino1, but can be distinguished using specific inhibitors

     • IRAK4 shows constitutive activity while IRAK1 requires stimulation for activation

     • Include IRAK4-IN-1 (IRAK4 inhibitor) when measuring IRAK1 activity, and vice versa

  3. Expression pattern analysis:

     • IRAK family members show tissue-specific expression patterns

     • IRAK3/M is primarily expressed in monocytes/macrophages

     • Use tissue-specific controls when validating antibody specificity

  4. Functional discrimination:

     • IRAK4 deficiency blocks both MyD88 and IRAK1-dependent pathways

     • IRAK1 deficiency has more selective effects on downstream signaling

     • Design rescue experiments with individual family members to confirm specificity

  5. Advanced techniques:

     • Use isoform-specific qPCR to confirm expression at the mRNA level

     • Employ mass spectrometry with tryptic digestion to identify peptides unique to each IRAK family member

     • For interaction studies, use tagged constructs of specific IRAK family members

  These approaches ensure accurate discrimination between IRAK family members in complex experimental systems.